According to the research report titled ‘Global Sunitinib malate market Size study, by Type (Purity: >99%, Purity: >98%, Purity: >97%), by Application (Pancreatic Neuroendocrine Tumors, Kidney Cancer, Gastrointestinal stromal tumor) and Regional Forecasts 2021-2027’, available with Market Study Report, global sunitinib malate market size is projected to grow substantially over 2021-2027.
 

Rising pervasiveness of pancreatic cancer and technological advancements are the key factors driving global sunitinib malate market growth, cites the study.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3930293/
 

As per the American Cancer Society, more than 56,000 Americans were diagnosed with pancreatic cancer in 2017, with over 42,000 expected to die from the disease. Pancreatic cancers are more difficult to diagnose and remove than other tumors due to their relative inaccessibility. Thus, there is a high demand for sunitinib malate capsules to treat such cancers, which further adds to the market development.
 

For the unaware, sunitinib malate is a small-molecule drug that inhibits several tyrosine kinases in various receptors (RTKs). Its potential antineoplastic action makes it an effective medication in reducing cell proliferation and angiogenesis. Renal cancer, pancreatic neuroendocrine tumors, and gastrointestinal stromal tumors (GST) can all be treated using sunitinib capsules.
 

Notably, sunitinib was the first cancer medication to be approved for both renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor (GIST) at the same time.
 

Speaking of negatives, hefty cost of sutent, as well as research & development is likely to impede worldwide sunitinib malate industry expansion over 2021-2027.
 

Based on type, the market is split into purity: >97%, purity: >98%, and purity: >99%. As per application spectrum, the industry segmentation comprises gastrointestinal stromal tumor, kidney cancer, and pancreatic neuroendocrine tumors.
 

Elaborating on regional front, North America, Asia Pacific, Europe, and Latin America are the leading contributors to the overall industry progression. Of these, North America leads the overall market share owing to rising pervasiveness of pancreatic cancer.
 

On the other hand, Asia Pacific market is projected to accrue high profits by the year 2027, attributable to rising cognizance regarding pancreatic cancer in developing countries like China, India, and others.
 

Top firms operating in global sunitinib malate marketplace are Ferring Pharmaceuticals Inc., Dendreon Corporation, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Synthland Ltd., TargetMol (Target Molecule Corp.), J&K Scientific Ltd., Nanjing First Pharmaceutical Co. Ltd., Top Care Pharmacy, and Pfizer Inc.